160 results about "Non covalent" patented technology

This invention provides a tetrahedral antibody comprising a first, second, third, and fourth domain, wherein the first and second domains are Fab or Fc domains; wherein each of the first and second domains comprise a first polypeptide chain comprising a first N-terminus of the domain, and a second polypeptide chain comprising a second N-terminus of the domain; wherein the first N-terminus of the first domain and the first N-terminus of the second domain are joined to each other by a non-peptidyl linkage, which can be a covalent linkage or a non-covalent linkage between first and second dimerizing polypeptides attached to the first N-termini of the first and second domains, respectively; and wherein the third and fourth domains are attached at their respective C-termini to the second N-termini of the first and second domains, respectively, or the N-termini of the first and second dimerizing polypeptides.

The invention discloses an oligonucleotide intracellular nano delivery system based on polypeptide modification and application thereof. The system is composed of a periostin targeting sequence (SDSSD), a matrix metalloproteinase 2 (MMP2) response sequence (GPAGLLG), a cell penetrating sequence (RRRRRRRR, R9), a reactive oxygen species (ROS) scavenging and adhesion enhancing group (Gly-DOPA)) and a terminal dibenzocyclooctyne (DBCO) modified engineered polypeptide SDSSD-PEG5-YGFGG-GPAGLLG-R9-(G-DOPA) 3-K4-C-DBCO, and a target oligonucleotide miRNA-26a-A5-Azido modified by 5-polyadenylic acid (AAAAA) and an azide group (Azido), and the target oligonucleotide miRNA-26a-A5-Azido, the target oligonucleotide and assembling through a click chemical reaction and a non-covalent interaction. The nano system has good bone targeting, enzyme responsiveness, intracellular delivery effect and biological safety, can realize stable and efficient delivery of therapeutic oligonucleotides in vivo, and significantly improves the utilization efficiency and therapeutic potential of oligonucleotides. The oligonucleotide intracellular nano delivery system has a wide application prospect in the fields of clinical transformation and precise treatment of oligonucleotide drugs.

The invention discloses a salicylic acid-cyclodextrin-amino acid ternary inclusion compound and a preparation method thereof. The salicylic acid-cyclodextrin-amino acid ternary inclusion compound is formed by salicylic acid, amino acid and a cyclodextrin derivative through non-covalent bond interaction, the cyclodextrin derivative is a cross-linked beta-cyclodextrin polymer, salicylic acid molecules are included in a cavity of the cross-linked beta-cyclodextrin polymer, and the cross-linked beta-cyclodextrin polymer is a cross-linked beta-cyclodextrin polymer. And meanwhile, guanidyl or carboxyl of an amino acid side chain interacts with hydroxyl outside the cross-linked beta-cyclodextrin polymer or an exposed part of an included salicylic acid molecule. According to the invention, a cross-linked beta-cyclodextrin polymer is used, arginine is introduced as a synergist, a salicylic acid-cross-linked beta-cyclodextrin polymer-arginine ternary clathrate compound is constructed, and through charge neutralization and hydrogen bond network synergistic effect, clathration efficiency is significantly improved, and water solubility of salicylic acid is improved.

The invention is applicable to the technical field of polymer biomedical hydrogel materials, and provides a preparation method and application of multifunctional agarose-based particle composite hydrogel based on liquid-liquid phase separation, and the agarose-based particle composite hydrogel is a product formed by introducing microsphere particles into an agarose hydrogel body matrix; the microsphere particles are formed by a prepolymer and sodium lignin sulfonate through phase separation mediated by a composite behavior based on non-covalent interaction; the prepolymer is obtained by carrying out amine-epoxy reaction on an amino compound and an epoxy compound in water. According to the prepared agarose-based particle composite hydrogel, a microsphere particle structure is formed on the surface of an agarose matrix while positively charged amino groups and sodium lignin sulfonate are introduced, so that the multifunctional agarose-based particle composite hydrogel is prepared.

This invention belongs to the field of cosmetic technology, specifically a glycyrrhizin-based composite nanoparticle containing sclerotherapy, BPOXY, and collagen, along with its preparation method and applications. The invention first combines glycyrrhizin and glycyrrhizic acid via non-covalent bonds to obtain a glycyrrhizin-glycyrrhizic acid eutectic structure that overcomes the solubility problem of glycyrrhizin. Then, a BPOXY-collagen mixture is used to coat the glycyrrhizin-glycyrrhizic acid eutectic structure, yielding glycyrrhizin-based composite nanoparticles containing sclerotherapy, BPOXY, and collagen. The glycyrrhizin-based composite nanoparticles containing sclerotherapy, BPOXY, and collagen obtained using this method exhibit good water solubility of glycyrrhizin, a simple composition, high stability, and minimal risk of allergic reactions. Furthermore, it enhances the skin permeability of glycyrrhizin, collagen, and BPOXY, resulting in a synergistic effect and improved bioavailability.

This invention discloses an AfBPP-based active molecular probe for thiostreptin, its preparation, and its application, belonging to the field of chemical biology. This invention introduces a bifunctional tag integrating a photocrosslinking group (bisacrididine) and a bioorthogonal reactive group (alkynyl group) into the structure of thiostreptin. While retaining the original biological activity of the parent compound, it endows the probe with highly efficient probe function, solving the technical problem of target loss during washing and purification of traditional non-covalent probes. After target labeling, the probe can specifically connect to reporter groups such as fluorescein or biotin through click-chemical reactions, achieving efficient enrichment of drug targets. Combined with mass spectrometry analysis, it enables global identification of potential targets in cells or complex biological samples at the omics level, such as chemical proteomics, providing a powerful molecular tool for in-depth revelation of the potential targets and pharmacological mechanisms of thiostreptin.

The present disclosure provides novel and improved IL-15 fusion proteins for treating cancer and other disorders. In various embodiments, the fusion protein of the present invention has two functional domains: an IL-15 / IL-15RαSushi domain (also referred to herein as "IL-15 / IL-15RαSushi complex") and an Fc domain, each of which can take different forms and is configured so that IL-15 is fused to the C-terminus of the Fc domain and co-expressed and non-covalently complexed with IL-15RαSushi. Importantly, the fusion protein of the present invention solves several defects observed in the IL-15 therapeutic agents evaluated to date; specifically, the fusion protein shows an extended half-life of IL-15 in vivo and exhibits better preclinical activity than rIL-15 or related cytokine therapeutics.

The invention belongs to the technical field of medicines, and discloses a chrysin and piperazine eutectic, a preparation method, a composition and application thereof. Specifically, the invention discloses an eutectic substance formed by combining chrysin and piperazine through a non-covalent bond, and the molecular formula of the eutectic substance is (C15H10O4). (C4H10N2) 0.5, the invention relates to a preparation method of a chrysin and piperazine eutectic. The chrysin and piperazine eutectic is applied to preparation of drugs with the effects of preventing and treating cardiovascular diseases, resisting oxidation, resisting cancer, resisting virus, resisting hypertension, reducing blood fat, reducing blood sugar, resisting bacteria, diminishing inflammation and the like.

The invention belongs to the field of natural plant extraction, and particularly relates to a method for extracting volatile oil from pepper. The method comprises the following steps: pulverizing a pepper raw material to obtain pepper powder, protecting an active component and modified maltodextrin, mixing, soaking the pepper powder in an obtained efficient leaching suspension, ultrasonically crushing the soaked mixture, and carrying out primary extraction to obtain primary extracted oil with obviously improved purity; the preparation method comprises the following steps: mixing a composite solvent formed through non-covalent interaction and combination with primarily extracted oil, filtering, carrying out molecular distillation on the obtained permeate, reducing the boiling point of an active ingredient by the composite solvent through a solvation effect, reducing thermal degradation, and remarkably improving the purity of the active ingredient while retaining the flavor through non-covalent pre-assembly-molecular distillation synergy. Light-phase fractions are collected after molecular distillation, and the prepared pepper volatile oil is high in active ingredient content, good in flavor retention, few in impurities and pure in color.

The application relates to a fusion protein and application thereof in the field of biotechnology. A polypeptide fragment for specifically recognizing a single-molecule phospholipid membrane and a polypeptide fragment for specifically recognizing a tissue or a cell are connected to form a fusion protein which can be specifically combined to a fat body surface in a non-covalent manner, so that precise targeting of the fat body is realized. The fat body targeting peptide segment can be widely used in the fields of precise drug delivery and vaccine preparation, so as to be used for treating diseases such as cancer, infectious diseases and metabolic diseases. Lung tissues and breast cancer cells are taken as target points, and good targeting of the fat body is realized.

Provided is a method for improving the stability of urate oxidase. The inventors have discovered that combining an active ingredient urate oxidase or chemically modified urate oxidase with a stabilizer xanthine through a non-covalent bond can significantly improve the in vivo and in vitro stability of urate oxidase and chemically modified urate oxidase in the form of a tetramer, thereby effectively improving the stability of urate oxidase.

The invention relates to the technical field of biological medicine, and particularly discloses an NSD protein targeted inhibitor and a preparation method thereof.The NSD protein targeted inhibitor is formed by assembling RK-0080552, rosmarinic acid, ferulic acid and TAT cell-penetrating peptide through non-covalent bonds, amino of the RK-0080552, phenolic hydroxyl of the rosmarinic acid and phenolic hydroxyl of the ferulic acid form a hydrogen bond, and the TAT cell-penetrating peptide forms a non-covalent bond. Arginine residues of the TAT cell-penetrating peptide are combined with carboxyl groups of rosmarinic acid and ferulic acid through electrostatic interaction to form a stable three-dimensional supramolecular structure; the preparation method comprises the following steps: respectively dissolving the components, mixing and crystallizing in proportion, washing, homogenizing at high pressure, and freeze-drying to obtain the NSD protein targeted inhibitor. According to the invention, drug activity enhancement and targeted delivery are realized through a supramolecular co-crystal technology, and the drug can be used for treating NSD2 high-expression tumors such as multiple myeloma and acute myelogenous leukemia, and has significant clinical application value.

The invention belongs to the technical field of semiconductor materials and devices, and discloses a photoelectric functional material for an organic transistor and a preparation method and application of the photoelectric functional material. A C-H activation strategy is adopted, two kinds of novel organic conjugated small molecules p-Ph2FTT and o-Ph2FTT containing F.H non-covalent bond conformation locks are synthesized, and the novel organic conjugated small molecules p-Ph2FTT and o-Ph2FTT containing F.H non-covalent bond conformation locks are synthesized. The molecule has excellent planarity, wide forbidden band (2.8 eV) and low HOMO energy level.

The application provides a mass spectrometry detection device and method for active protein-small molecule interaction, which uses a mass spectrometry sensor to obtain tandem mass spectrometry data of non-covalent complexes of active protein incubated with small molecule compounds at different concentration points; performs non-linear curve fitting on the concentration sequence of the small molecule compounds based on the ion combination rate of the protein binding small molecules at each concentration point, to obtain an apparent dissociation constant of the active protein-small molecule interaction; determines a local conformation change parameter of the active protein induced by small molecule binding and a potential binding domain of the small molecule; and performs fusion evaluation on the binding strength and conformation influence degree of the protein-small molecule interaction based on the apparent dissociation constant, the local conformation change parameter and the potential binding domain, to output a stability grade of the protein-small molecule interaction. Based on the above scheme, non-denatured state mass spectrometry detection of protein-small molecule complexes in a liquid phase environment can be realized.

The invention relates to organic gel as well as a preparation method and application thereof. The organic gel comprises an organic gelling agent and a solvent A. The preparation method comprises the following steps: mixing the organic gelling agent with the solvent A to prepare the organic gel. A stable gel system with a three-dimensional network structure is formed through non-covalent interaction of intermolecular hydrogen bonds, Van der Waals force and the like, the gel system is endowed with thermodynamic reversibility, self-repairing capability and environmental adaptability, the solvent A is wide in application range, and absolute configuration of chiral carbon atoms has no obvious influence on the property of the organic gel.

This invention provides a Panax notoginseng-Paris polyphylla supramolecular complex, its preparation method, cosmetic products, and applications. The Panax notoginseng-Paris polyphylla supramolecular complex is a complex formed by non-covalent bonding of Panax notoginseng extract (as the host molecule) and Paris polyphylla extract (as the guest molecule), with the host molecule encapsulating the guest molecule structure. The Panax notoginseng-Paris polyphylla supramolecular complex of this invention not only improves the water solubility of Paris polyphylla extract but also increases its skin permeability and reduces its cytotoxicity. The preparation method of this invention utilizes the synergistic effect of the active ingredients, resulting in strong compatibility and synergistic efficacy. It also slows down the release time of the active ingredients, extends their shelf life, and features a simple and easy-to-control process, stable granulation effect, and low production cost.

A system and method for determining a biological activity parameter of a ligand are disclosed, the system comprising a processor configured to: obtain ligand-protein complex structure data and reference biological activity data; determine ligand-protein complex interaction parameters indicative of intermolecular interaction data of the ligand-protein complex in a docking conformation; determine aggregated ligand-protein complex interaction parameters across a plurality of docking conformations; and determine the biological activity parameter based on the aggregated ligand-protein complex interaction parameters, wherein determining the ligand-protein complex interaction parameters comprises determining non-covalent parameters indicative of intermolecular interaction data of a ligand node and a protein node based on ligand and protein attributes and ligand-protein non-covalent parameters indicative of binding stability of a first non-covalent edge of a dispersion force type.

The invention relates to the technical field of analysis and test technologies and medical methods, and discloses a reagent and a method for molecular structure analysis of an estrogen isomer, which are based on cyclodextrin and are used for molecular structure analysis of an alpha / beta-E2 / E3 isomer. The reagent comprises gamma cyclodextrin (gamma-CD), beta-CD and a mixed aqueous solution of compounds containing different metal ion ligands, the molecular formula of the beta-CD is C42H70O35, the molecular weight of the beta-CD is 1134.98, and the compound containing the metal ions is salt of any metal ion or soluble alkali containing the metal ions. According to the method, an alpha / beta-E2 / E3 sample, CD, a compound containing metal ions, such as monovalent metal or divalent metal ions and the like are simply prepared into a mixed solution, then non-covalent compound ions of alpha / beta-E2 / E3-gamma-CD / beta-CD-containing metal ions are generated by utilizing electrospray ionization, and then the ion mobility spectrometry of the non-covalent compound ions is measured by utilizing an ion mobility spectrometry technology. And different position structure information of alpha / beta-E2 / E3 molecules can be obtained.

This invention discloses a layer-by-layer deposition modified ultrafiltration membrane with both antifouling and antibacterial properties, its preparation method, and its applications. Through layer-by-layer assembly technology, a tannic acid (TA) anion layer and a polyhexamethylene biguanide (PHMB) cation layer are alternately deposited on the surface of an ultrafiltration membrane. Under weakly alkaline conditions, electrostatic interactions, hydrogen bonding, Schiff base reactions, and Michael addition reactions are simultaneously utilized to achieve both non-covalent and covalent bonding, constructing a stable and dense integrated antibacterial-antifouling composite coating. This coating has a contact-type antibacterial structure, which can effectively kill bacteria in water and inhibit biofilm formation at the source. Simultaneously, it significantly improves the hydrophilicity of the membrane surface, reduces pollutant adsorption and deposition, and achieves synergistic enhancement of antibacterial and antifouling properties. The preparation process of this invention is mild, simple, low-cost, and environmentally friendly. The modified membrane exhibits high flux retention, excellent separation performance, and excellent operational stability, and can be widely applied in water treatment scenarios such as municipal wastewater treatment.

The invention discloses a hydrogel dressing with antibacterial property, antioxidant property and pH responsiveness as well as a preparation method and application of the hydrogel dressing, and belongs to the technical field of biomedical materials. An aldehyde group generated after ring opening of genipin as a chemical cross-linking agent and an amino group in a high-molecular polymer are subjected to a Schiff base reaction to realize chemical cross-linking, puerarin molecules are self-assembled through non-covalent bonds including hydrogen bonds and hydrophobic interaction, and a gel network is formed; and Ag-coated CR composite nanoparticles synthesized by a microalgae extract and silver nitrate are loaded. The multifunctional hydrogel material provided by the invention has antibacterial, antioxidant and pH-responsive properties, shows excellent antibacterial ability for common pathogenic bacteria such as escherichia coli, staphylococcus aureus and the like, and can effectively inhibit wound infection.

The invention relates to the technical field of radiopharmaceuticals, and discloses a targeted GPC3 polypeptide ligand, which has a structural general formula: C-L-P, wherein C is a chelating group; l is a linker; p is a targeted phosphatidylinositol proteoglycan-3 (GPC3) polypeptide pharmacodynamic group; the linker is a covalent linker or a reversible non-covalent linker. The invention has the following technical effects: by introducing the covalent linker or the reversible non-covalent linker, the chemical structure of the targeted GPC3 polypeptide ligand is optimized, the targeting property of the targeted GPC3 polypeptide radiopharmaceutical is improved, and the pharmacokinetic characteristics are improved; the defects that an existing targeted GPC3 polypeptide radiopharmaceutical is low in tumor uptake, short in tumor residence time, poor in pharmacokinetic characteristic and the like are overcome. The invention further discloses a targeted GPC3 polypeptide radiopharmaceutical as well as a preparation method and application of the targeted GPC3 polypeptide radiopharmaceutical.

The invention discloses a natural polymer polyelectrolyte microsphere as well as a preparation method and application thereof, the microsphere is of a covalent and non-covalent double-crosslinking network structure formed by crosslinking natural polymer and polyelectrolyte, and the modification degree of the crosslinked natural polymer is 1.0-50.0%; the natural polymer is a compound containing more than two carboxyl groups or amino groups or a combination of the carboxyl groups and the amino groups; and the polyelectrolyte is a compound containing more than two carboxyl groups or amino groups or a combination of the carboxyl groups and the amino groups. The preparation method comprises the following steps: S1, dissolving a natural polymer and a polyelectrolyte in a water phase to generate an electrostatic complex; s2, adding enzyme into the electrostatic complex and incubating to form microspheres; and S3, adding a condensing agent and / or a cross-linking agent, removing the unreacted condensing agent and / or cross-linking agent, and sterilizing to obtain the natural polymer polyelectrolyte microspheres. The microsphere can be used as an embolism agent in an interventional technology or a separation and purification medium of protein, antibodies and drugs or a cell and drug carrier system, or as an implant material for orthopedics, surgery, ophthalmology and medical beauty.

The present invention provides a drug-loaded nanoparticle composition suitable for drug delivery in vivo, wherein the drug-loaded nanoparticle composition is formed in the form of a non-covalent bond and comprises an active ingredient, cyclodextrin, and albumin. Drug-loaded nanoparticles or the composition thereof in the present invention are stable in a solution state, avoiding cumbersome operations of reconstitution and redissolution. Compared with a known freeze-dried powder of nanoparticles containing albumin, the nanoparticles in the present invention have a particle size of less than 150 nm, can remain stable for at least 7 days or more without change, and can be predicted to be stable for a long time.

An amphiphilic drug carrier and the use thereof in the ocular delivery of a biomacromolecular drug. The amphiphilic drug carrier is capable of penetrating the ocular mucus barrier, loading a biomacromolecular drug by means of non-covalent interaction, and delivering the biomacromolecular drug for the treatment of fundus diseases.

A nanoparticle complex comprises a bifunctional conjugate capable of non-covalently binding to lipid nanoparticles in the nanoparticle complex.

The invention belongs to the technical field of synthesis of polysaccharide conjugate vaccines, and relates to a proteus mirabilis O3a O-antigen tetrasaccharide repeating unit containing an adamantane skeleton, an antigen and a polysaccharide conjugate vaccine. The active ingredients of the polysaccharide conjugate vaccine provided by the invention comprise a subject and an object, and the subject and the object are mutually combined through non-covalent interaction; the subject comprises a compound of beta-cyclodextrin and carrier protein, and the guest comprises maltotriose containing an adamantane skeleton or a proteus mirabilis O3a O-antigen containing an adamantane skeleton. The proteus mirabilis O3a O-antigen tetrasaccharide repeating unit containing the adamantane skeleton is successfully synthesized with high stereoselectivity and excellent yield by adopting a [2 + 1 + 1] graded assembly strategy, and the research can lay a firmer theoretical and practical foundation for research and development of proteus mirabilis resistant vaccines.

The application provides a temperature-resistant adhesion type supramolecular polymer gel plugging particle and a preparation method and application thereof, and belongs to the technical field of oil field chemicals. The temperature-resistant adhesion type supramolecular polymer gel plugging particle is prepared from the following raw materials in a mass percentage: 5-10% of a high molecular polymer, 10-20% of a methyl-containing organic compound, 1-5% of a natural high molecular material, 0.1-1% of a phenyl-containing compound, 1-5% of inorganic particles, 0.1-1% of an initiator, and the balance of water. The application introduces a bonding functional monomer with strong adhesion performance into the polymer gel, and cooperates with various temperature-resistant functional groups and various non-covalent bond interactions, so that the temperature resistance, strength and wall adhesion capacity of the polymer gel particle are improved. The obtained supramolecular polymer gel plugging particle is high in temperature resistance, high in strength, high in adhesion and capable of effectively plugging a fractured formation.

The invention belongs to the technical field of biomedical materials and tissue engineering, and particularly relates to hydrogel for treating ulcerative colitis and a preparation method thereof. The hydrogel is prepared from four functional components including oxidized dextran, chitosan, L-arginine and trithiohydracrylic acid through synergistic crosslinking, wherein the four functional components include the oxidized dextran, the chitosan, the L-arginine and the trithiohydracrylic acid; an aldehyde group of the oxidized dextran and an amino group of the chitosan are subjected to a Schiff base reaction to form a dynamic covalent cross-linked network, and a basic skeleton of the hydrogel is formed; l-arginine and guanidyl are integrated into the dynamic covalent cross-linked network through amino of the L-arginine, and trimercaptopropionic acid and carboxyl of the trimercaptopropionic acid are integrated into the dynamic covalent cross-linked network through a covalent bond or a non-covalent effect through sulfydryl of the trimercaptopropionic acid, so that a multi-site synergistic cross-linked structure is formed. The invention can solve the technical problems of single function, weak targeting property, insufficient oxidation resistance, short mucous membrane residence time, side effect risk caused by loading of exogenous drugs, limited curative effect, drug resistance and the like of the traditional treatment material.

The presently disclosed subject matter generally relates to polymer networks having covalent crosslinks, non-covalent crosslinks, and ionic side groups, and methods of making and using same. Specifically, the disclosed polymer networks can be incorporated into membranes, which can be useful in, for example, electrodialysis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.